Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.17
+0.32 (2.70%)
Mar 4, 2026, 10:22 AM EST - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 20, which predicts an increase of 64.34% from the current stock price of 12.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +64.34% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +64.34% | Feb 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +64.34% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +64.34% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +64.34% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
38.48M
from 25.42M
Increased by 51.37%
Revenue Next Year
56.56M
from 38.48M
Increased by 46.98%
EPS This Year
-4.28
from -3.47
EPS Next Year
-4.40
from -4.28
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 63.0M | 89.3M | |||
| Avg | 38.5M | 56.6M | |||
| Low | 14.7M | 25.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 147.8% | 131.9% | |||
| Avg | 51.4% | 47.0% | |||
| Low | -42.2% | -34.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|
| High | -3.18 | -3.35 | ||
| Avg | -4.28 | -4.40 | ||
| Low | -4.83 | -4.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.